目的 探討紫杉醇聯(lián)合順鉑治療中晚期宮頸癌的療效及對患者鱗狀上皮癌抗原（SCC-Ag）、細胞角蛋白19片段抗原21-1（CYFRA21-1）水平的影響。方法 選取惠州市惠東縣婦幼保健院實施化療的中晚期宮頸癌患者120例，研究對象收集時間2013年1月—2015年7月，根據(jù)化療方案分為A組（紫杉醇聯(lián)合順鉑治療）60例、B組（絲裂霉素+順鉑+5-FU治療）60例，兩組患者均經(jīng)行3～5個療程的治療。對比兩組患者臨床療效及化療前、化療結(jié)束后2周患者血清CYFRA21-1、SCCAg的水平，并比較兩組預后情況。結(jié)果 A組患者的緩解率為84.21%，B組為67.86%，A組顯著高于B組（P<0.05）；A組患者的總有效率96.49%與B組患者的92.86%比較差異不具有統(tǒng)計學意義。治療前，A組和B組患者的血清CYFRA21-1、SCC-Ag水平差異無統(tǒng)計學意義；治療后，兩組患者的血清CYFRA21-1、SCC-Ag水平較本組治療前均顯著的降低（P<0.05）；且A組血清CYFRA21-1、SCC-Ag水平低于B組（P<0.05）。術(shù)后1、2、3年生存率比較，兩組差異均無統(tǒng)計學意義。A組患者的中位生存時間29.0個月顯著的長于B組患者的22.0個月，差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 紫杉醇聯(lián)合順鉑治療中晚期宮頸癌的近期療效優(yōu)于絲裂霉素+順鉑+5-FU，但是對患者遠期生存率的提高并不顯著。

Objective To investigate the effect of paclitaxel and cisplatin in the treatment of advanced cervical cancer and its effect on squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) level.Methods 120 patients with advanced cervical cancer chemotherapy in Huizhou Huidong County Maternal and Child Health Hospitall were selected, the study collected in January 2013 to July 2015, according to the chemotherapy were divided into A group (paclitaxel combined with cisplatin in the treatment of 60 cases (group B), mitomycin and cisplatin + 5-FU therapy) 60 cases, treatment group two patients were treated for 3-5 courses.Results Remission in A group were significantly higher than the rate of 84.21% of the 67.86% patients in the B group (P<0.05). A group of patients with total efficiency of 96.49% and 92.86% patients in the B group compared the difference was not statistically significant. Before treatment, the differences of serum CYFRA21-1, SCC-Ag levels in A group and B group were not statistically significant. After treatment, the patients in the A group serum CYFRA21-1, SCC-Ag levels were significantly lower than in group B (P<0.05), serum CYFRA21-1 and SCC-Ag levels in both groups were significantly reduced than before treatment (P<0.05). Survival rate after 1 years, 2 years, 3 years in A group and B group, there were no significant differences. The median survival time in the A group was 29 months, significantly longer than the 22 months in the B group, and the difference was statistically significant (Log, Rank (Mantel-Cox),=5.220, P=0.022 < 0.05). Conclusion The short-term efficacy of paclitaxel combined with cisplatin in the treatment of advanced cervical cancer is better than that of mitomycin C + cisplatin +5-FU, but the long-term survival rate of the patients is not significant.